{"id":5366,"date":"2022-10-23T14:01:00","date_gmt":"2022-10-23T13:01:00","guid":{"rendered":"https:\/\/catapult.org.uk\/?post_type=case_study&#038;p=5366"},"modified":"2023-08-21T12:58:04","modified_gmt":"2023-08-21T11:58:04","slug":"alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration","status":"publish","type":"case_study","link":"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/","title":{"rendered":"Alchemab Therapeutics secures private funding for new treatments following collaboration"},"content":{"rendered":"\n<div style=\"height:54px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:10%\"><\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:90%\">\n<h1 class=\"wp-block-heading\">Alchemab Therapeutics secures private funding for new treatments following collaboration<\/h1>\n\n\n\n<div style=\"height:46px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/MDC-1-1024x683.jpg\" alt=\"\" class=\"wp-image-5367\" srcset=\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/MDC-1-1024x683.jpg 1024w, https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/MDC-1-300x200.jpg 300w, https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/MDC-1-768x512.jpg 768w, https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/MDC-1-1536x1024.jpg 1536w, https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/MDC-1-2048x1365.jpg 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure><\/div>\n\n<div style=\"background-color: white;background:\"\n                    class=\"pt-5 pb-5  alignwide\"\n                >    <div class=\"container impactGrid\">        <div class=\"row\">            <div class=\"col-md-6 border-top-dashed border-bottom-sm-dashed border-right-sm-dashed pl-0 pr-0 pt-4 pb-4 d-flex align-items-center\"\n                                style=\"border-color:#FE5000;color:#FE5000;\"\n                            >                    <div class=\"col-md-8 d-flex flex-column justify-content-center\">                        <span class=\"figure\"\n                                            style=\"font-size:2.8125rem\"\n                                        >\n                                            \n                                        <\/span>\n\n                                        <br\/>\n\n                                        <div class=\"raleway font-weight-bold\">\n                                            Significant private funding secured for Alchemab&#8217;s unique drug discovery platform\n                                        <\/div>\n\n                                    <\/div>\n\n                                    <div class=\"col-4 col-sm-2 col-md-4 d-flex justify-content-center\"><img loading=\"lazy\" decoding=\"async\" width=\"70\" height=\"70\" class=\"img-fluid\" style=\"object-fit:contain\" src=\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2020\/12\/icons-sweets.svg\">                    <\/div>\n\n                            <\/div>            <div class=\"col-md-6 border-top-dashed border-bottom-dashed pr-0 pl-0 pt-4 pb-4 d-flex align-items-center\"\n                                style=\"border-color:#FE5000;color:#FE5000;\"\n                            >                    <div class=\"col-md-8 d-flex flex-column justify-content-center\">                        <span class=\"figure\"\n                                            style=\"font-size:2.8125rem\"\n                                        >\n                                            \n                                        <\/span>\n\n                                        <br\/>\n\n                                        <div class=\"raleway font-weight-bold\">\n                                            Collaboration extended to focus on  Alzheimer\u2019s Disease\n                                        <\/div>                    <\/div>\n\n                                    <div class=\"col-4 col-sm-2 col-md-4 d-flex justify-content-center\">                            <img loading=\"lazy\" decoding=\"async\" width=\"70\" height=\"70\" class=\"img-fluid\" style=\"object-fit:contain\" src=\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2020\/12\/dna-solid.svg\">                    <\/div>\n\n                            <\/div>\n\n                        <\/div>    <\/div>\n\n                <\/div>\n\n\n<div style=\"height:0px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p>In 2021 Alchemab and Medicines Discovery Catapult (MDC) collaborated on a Huntington\u2019s disease focussed project, which supported Alchemab in securing significant private investment.&nbsp;<\/p>\n\n\n\n<p>Alchemab pioneers a data-driven approach to antibody therapeutics by identifying highly resilient subjects and learning how their antibodies overcome or resist disease. It uses them to develop therapeutic products for broader use in patients who lack the protective response.&nbsp;<\/p>\n\n\n\n<p>This funding enabled Alchemab to exploit its target-agnostic drug discovery platform further, focusing on developing novel therapeutics for hard-to-treat neurodegenerative diseases and cancers. <\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p>The Alchemab and MDC collaboration was extended in 2022 to functionally characterise antibodies from resilient patients with Alzheimer\u2019s disease and frontotemporal dementia. Alchemab\u2019s approach, developing new therapeutics founded on natural resilience to disease rather than the disease itself, combined with MDC\u2019s technologies and expertise, significantly improves understanding of the pathophysiology and treatment opportunities for Huntington\u2019s disease and Alzheimer\u2019s disease. This approach has great potential to be applied to many other areas of currently unmet patient needs.<\/p>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:0px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-group is-nowrap is-layout-flex wp-container-core-group-is-layout-ad2f72ca wp-block-group-is-layout-flex\"><div\n  class=\"mt-5 mb-5 blockQuote  position-relative\"\n  style=\"padding-left: 40px;border-left: solid #393D48 10px;\">\n    <svg class=\"pb-3\" width=\"26\" height=\"40\" viewBox=\"0 0 20 17\"\n    style=\"fill-rule:evenodd;clip-rule:evenodd;stroke-linejoin:round;stroke-miterlimit:2;\">\n    <path\n      d=\"M2.173,0l-2.173,7.704l0,8.796l8.15,0l-0,-8.667l-2.415,-0l1.328,-7.833l-4.89,0Zm11.35,0l-2.173,7.704l0,8.796l8.15,0l0,-8.667l-2.415,-0l1.329,-7.833l-4.891,0Z\"\n      style=\"fill:#FE5000;fill-rule:nonzero;\" \/>\n  <\/svg>\n      <p class=\"quoteContent\" style=\"color:black;\">\n    <em>We are very pleased to extend our collaboration with Medicines Discovery Catapult. After great success in our Huntington\u2019s disease program, we are positioned to continue to discover and develop potentially transformative therapies.<\/em>  <\/p>\n  \n    <div class=\"quoteFooterContent pt-3 pb-3\"\n    style=\"font-size: 1.125rem; color: black;\">\n    <strong>Dr Young T. Kwon, PhD <\/strong><br>Chief Executive Officer, Alchemab Therapeutics  <\/div>\n  \n  \n    <div class=\"text-right\">\n    <svg width=\"26\" height=\"40\" viewBox=\"0 0 20 17\"\n      style=\"fill-rule:evenodd;clip-rule:evenodd;stroke-linejoin:round;stroke-miterlimit:2;\">\n      <path\n        d=\"M17.464,16.594l2.19,-7.748l-0,-8.846l-8.214,0l-0,8.716l2.434,0l-1.339,7.878l4.929,-0Zm-11.44,-0l2.19,-7.748l0,-8.846l-8.214,0l0,8.716l2.434,0l-1.339,7.878l4.929,-0Z\"\n        style=\"fill:#FE5000;fill-rule:nonzero;\" \/>\n    <\/svg>\n  <\/div>\n  <\/div>\n<\/div>\n\n\n\n<div style=\"height:0px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div style=\"height:0px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-image is-style-rounded\">\n<figure class=\"aligncenter size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/09\/AlchemabMDC-1024x683.jpg\" alt=\"\" class=\"wp-image-5609\" srcset=\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/09\/AlchemabMDC-1024x683.jpg 1024w, https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/09\/AlchemabMDC-300x200.jpg 300w, https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/09\/AlchemabMDC-768x512.jpg 768w, https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/09\/AlchemabMDC-1536x1024.jpg 1536w, https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/09\/AlchemabMDC-2048x1365.jpg 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure><\/div>\n\n\n<p><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:10%\"><\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\"><\/div>\n<\/div>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In 2021 Alchemab and Medicines Discovery Catapult (MDC) collaborated on a Huntington\u2019s disease focussed project, which supported Alchemab in securing significant private investment.\u00a0<\/p>\n","protected":false},"featured_media":5367,"template":"","meta":{"_external_link_checkbox":false,"_external_link":"","_event_date":"","_featured_case_study":false},"categories":[10],"tags":[61,63],"class_list":["post-5366","case_study","type-case_study","status-publish","has-post-thumbnail","hentry","category-medicines-discovery","tag-catapult-highlights","tag-leverage"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Alchemab Therapeutics secures private funding for new treatments following collaboration - The Catapult Network<\/title>\n<meta name=\"description\" content=\"In 2021 Alchemab and Medicines Discovery Catapult (MDC) collaborated on a Huntington\u2019s disease focussed project, which supported Alchemab in securing significant private investment.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alchemab Therapeutics secures private funding for new treatments following collaboration - The Catapult Network\" \/>\n<meta property=\"og:description\" content=\"In 2021 Alchemab and Medicines Discovery Catapult (MDC) collaborated on a Huntington\u2019s disease focussed project, which supported Alchemab in securing significant private investment.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/\" \/>\n<meta property=\"og:site_name\" content=\"The Catapult Network\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-21T11:58:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/MDC-1-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"3840\" \/>\n\t<meta property=\"og:image:height\" content=\"2560\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@Catapult_UK\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/\",\"url\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/\",\"name\":\"Alchemab Therapeutics secures private funding for new treatments following collaboration - The Catapult Network\",\"isPartOf\":{\"@id\":\"https:\/\/catapult.org.uk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/MDC-1-scaled.jpg\",\"datePublished\":\"2022-10-23T13:01:00+00:00\",\"dateModified\":\"2023-08-21T11:58:04+00:00\",\"description\":\"In 2021 Alchemab and Medicines Discovery Catapult (MDC) collaborated on a Huntington\u2019s disease focussed project, which supported Alchemab in securing significant private investment.\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/#primaryimage\",\"url\":\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/MDC-1-scaled.jpg\",\"contentUrl\":\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/MDC-1-scaled.jpg\",\"width\":3840,\"height\":2560,\"caption\":\"Two women with pippettes\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/catapult.org.uk\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Case Studies\",\"item\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Alchemab Therapeutics secures private funding for new treatments following collaboration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/catapult.org.uk\/#website\",\"url\":\"https:\/\/catapult.org.uk\/\",\"name\":\"The Catapult Network\",\"description\":\"The Innovate UK Catapult Network\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/catapult.org.uk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alchemab Therapeutics secures private funding for new treatments following collaboration - The Catapult Network","description":"In 2021 Alchemab and Medicines Discovery Catapult (MDC) collaborated on a Huntington\u2019s disease focussed project, which supported Alchemab in securing significant private investment.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/","og_locale":"en_GB","og_type":"article","og_title":"Alchemab Therapeutics secures private funding for new treatments following collaboration - The Catapult Network","og_description":"In 2021 Alchemab and Medicines Discovery Catapult (MDC) collaborated on a Huntington\u2019s disease focussed project, which supported Alchemab in securing significant private investment.\u00a0","og_url":"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/","og_site_name":"The Catapult Network","article_modified_time":"2023-08-21T11:58:04+00:00","og_image":[{"width":3840,"height":2560,"url":"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/MDC-1-scaled.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@Catapult_UK","twitter_misc":{"Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/","url":"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/","name":"Alchemab Therapeutics secures private funding for new treatments following collaboration - The Catapult Network","isPartOf":{"@id":"https:\/\/catapult.org.uk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/#primaryimage"},"image":{"@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/#primaryimage"},"thumbnailUrl":"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/MDC-1-scaled.jpg","datePublished":"2022-10-23T13:01:00+00:00","dateModified":"2023-08-21T11:58:04+00:00","description":"In 2021 Alchemab and Medicines Discovery Catapult (MDC) collaborated on a Huntington\u2019s disease focussed project, which supported Alchemab in securing significant private investment.\u00a0","breadcrumb":{"@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/#primaryimage","url":"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/MDC-1-scaled.jpg","contentUrl":"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/MDC-1-scaled.jpg","width":3840,"height":2560,"caption":"Two women with pippettes"},{"@type":"BreadcrumbList","@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/alchemab-therapeutics-secures-private-funding-for-new-treatments-following-collaboration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/catapult.org.uk\/"},{"@type":"ListItem","position":2,"name":"Case Studies","item":"https:\/\/catapult.org.uk\/our-work\/case-studies\/"},{"@type":"ListItem","position":3,"name":"Alchemab Therapeutics secures private funding for new treatments following collaboration"}]},{"@type":"WebSite","@id":"https:\/\/catapult.org.uk\/#website","url":"https:\/\/catapult.org.uk\/","name":"The Catapult Network","description":"The Innovate UK Catapult Network","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/catapult.org.uk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"_links":{"self":[{"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/case_study\/5366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/case_study"}],"about":[{"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/types\/case_study"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/media\/5367"}],"wp:attachment":[{"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/media?parent=5366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/categories?post=5366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/tags?post=5366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}